Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
Copenhagen Respiratory Research
2,000 participants
Mar 10, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this cluster randomized controlled trial is to determine the optimal treatment for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 40 years old diagnosed with chronic obstructive pulmonary disease with acute exacerbation. The main question is whether there is a difference in readmission for COPD excerbation or all cause mortality within thirty days. Participants will randomized to receive treatment with either hydrocortisone or prednisolone.
Eligibility
Inclusion Criteria2
- Age ≥40 years
- Chronic obstructive pulmonary disease with acute exacerbation, unspecified: ICDJ44
Exclusion Criteria3
- All diagnoses that would merit treatment with a specific corticosteroid
- Pregnant or breastfeeding women
- Active tuberculosis or invasive fungal infection
Interventions
ATC code: H02AB06. Can be changed to Prednisolone 50 mg orally.
ATC-code: H02AB09. Can be changed to 50 mg x 4 daily orally if appropriate.
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06892210